NYSE:USNA - USANA Health Sciences Stock Price, News, & Analysis

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

USANA Health Sciences declared that its board has authorized a share repurchase plan on Wednesday, July 26th 2017, which permits the company to buyback $64,600,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase up to 46% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board of directors believes its shares are undervalued.

USANA Health Sciences, Inc. (NYSE:USNA) announced its quarterly earnings data on Tuesday, July, 24th. The company reported $1.36 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.11 by $0.25. The company had revenue of $301.50 million for the quarter, compared to analyst estimates of $278.41 million. USANA Health Sciences had a net margin of 7.16% and a return on equity of 29.50%. The firm's quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.98 earnings per share. View USANA Health Sciences' Earnings History.

USANA Health Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, October, 23rd 2018. View Earnings Estimates for USANA Health Sciences.

USANA Health Sciences issued an update on its FY18 earnings guidance on Tuesday, July, 24th. The company provided earnings per share guidance of $4.75-5.05 for the period, compared to the Thomson Reuters consensus estimate of $4.56. The company issued revenue guidance of $1.15 billion, compared to the consensus revenue estimate of prior $4.25-4.55.

2 equities research analysts have issued 12-month price objectives for USANA Health Sciences' shares. Their predictions range from $135.00 to $135.00. On average, they anticipate USANA Health Sciences' stock price to reach $135.00 in the next year. This suggests a possible upside of 3.7% from the stock's current price. View Analyst Price Targets for USANA Health Sciences.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for USANA Health Sciences.

Some companies that are related to USANA Health Sciences include STADA Arzneimittel (STDAF), Tilray (TLRY), Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), GLG Life Tech (GLGLF), Cyanotech (CYAN), ImmuDyne (IMMD), FitLife Brands (FTLF), Tauriga Sciences (TAUG) and Nutra Pharma (NPHC).

News articles about USNA stock have been trending somewhat positive on Monday, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. USANA Health Sciences earned a media and rumor sentiment score of 0.07 on Accern's scale. They also assigned news headlines about the company an impact score of 45.74 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for USANA Health Sciences.

USANA Health Sciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include WENTZ MYRON W (43.80%), Renaissance Technologies LLC (8.68%), BlackRock Inc. (3.98%), Acadian Asset Management LLC (3.71%), Dimensional Fund Advisors LP (3.00%) and FMR LLC (0.99%). Company insiders that own USANA Health Sciences stock include Daniel A Macuga, David Mulham Mulham, Deborah Woo, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, James Bramble, Jim Brown, Kevin Guest, Myron W Wentz, Paul A Jones, Robert Auciaux and Walter Noot. View Institutional Ownership Trends for USANA Health Sciences.

USNA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Schroder Investment Management Group, Dimensional Fund Advisors LP, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Wells Fargo & Company MN, Cubist Systematic Strategies LLC, Mackay Shields LLC and Russell Investments Group Ltd.. Company insiders that have sold USANA Health Sciences company stock in the last year include Daniel A Macuga, David Mulham Mulham, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, James Bramble, Jim Brown, Kevin Guest, Myron W Wentz, Paul A Jones and Walter Noot. View Insider Buying and Selling for USANA Health Sciences.

USNA stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Robeco Institutional Asset Management B.V., BlackRock Inc., Millennium Management LLC, Federated Investors Inc. PA, Sensato Investors LLC and Caisse DE Depot ET Placement DU Quebec. View Insider Buying and Selling for USANA Health Sciences.

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of USNA stock can currently be purchased for approximately $130.20.

USANA Health Sciences has a market capitalization of $3.15 billion and generates $1.05 billion in revenue each year. The company earns $62.53 million in net income (profit) each year or $4.06 on an earnings per share basis. USANA Health Sciences employs 1,810 workers across the globe.

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]